Interim report
Page 1
November 04, 2026 National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: LALPATHLAB BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 Scrip Code: 539524 Sub: Outcome of Board Meeting held on November 04, 2026 Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”) Dear Sir/ Madam, Please take note that the Board of Directors in their meeting held today i.e. November 04, 2026, inter-alia considered, noted and approved the following(s): Financial Results 1. Un-audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Half Year ended September 30, 2026. A signed copy of the above Financial Results (Standalone & Consolidated) along with Limited Review Report issued by Statutory Auditors thereon under Regulation 33 of the Listing Regulations is attached herewith as “Annexure- A”. Interim Dividend 2. Declaration of 2nd Interim Dividend of INR 5/- per equity share (@ 50% on a face value of INR 10/- each) for the financial year 2026 -27. The record date for the purpose of payment of 2 nd Interim Dividend shall be November 11, 2026. The 2 nd Interim Dividend will be paid within 30 days of its declaration. Appointment of Director 3. Based on the recommendation of Nomination and Remuneration Committee, the Ap pointment of Ms. Vasuta Agarwal (DIN: 07480674) as an Additional Director designated as a Non- Executive Independent Director on the Board of the Company, for a term of three (3) consecutive years commencing from November 04, 2026, subject to approval of Members of the Company through postal ballot. Please also take note that Ms. Vasuta Agarwal is not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India or any other such Authority. The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as amended from time to time are enclosed herewith as “Annexure – B”.
Page 2
Fur ther investment in Subsidiary Company 4. Fur ther inves tment(s) of an amount upto INR 49.5 Cr ores in Dr. Lal PathLabs FZCO, (“LPL Dubai”), a Wholly Owned Subsidiary of the Company, in one or more tranches, for meeting its business and operational requirements, including making further investment in its subsidiary, Sunshine Healthcare Limited (“SHL”), Ghana. The di sclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as amended from time to time is enclosed herewith as “Annexure – C”. The Board Meeting commenced at 11:49 A.M. (IST) and concluded at 01:20 P.M. (IST). We request you to please take the same on record. Thanking You, Yours Faithfully, For Dr. Lal PathLabs Limited Vinay Gujral Company Secretary & Compliance Officer Encl.: As above
Page 3
Deloitte Haskins & Sells LLP Chartered Accountants 7th Floor Building 10 Tower B DLF Cyber City Complex DLF City Phase II Gurugram�122 002 Haryana, lndia Tei: +91124 679 2000 Fax: +91124 679 2012 INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED CONSOUDATED FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF Dr. LAL PATHLABS UMITED 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Dr. Lal Pathlabs Limited ("the Parent") and Its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and six months ended September 30, 2026 ('the Statement'), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules Issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review, 3. We conducted our review of the Statement In accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (!CAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. The Statement includes the results of the following entitles: a) Dr. Lal PathLabs Limited, the Parent company b) Pallwal Diagnostics Private Limited, a subsidiary company c) Dr. Lal PathLabs Nepal Private Limited, a subsidiary company d) Dr. Lal PathLabs Bangladesh Private Limited, a subsidiary company e) Dr. Lal Ventures Private Limited, a subsidiary company f) Neuome Technologies Private Limited (w,e.f August 27, 2026), an Associate Company g) PathLabs Unifiers Private Limited, a subsidiary company h) Centrapath Labs Private Limited, a step-down subsidiary company i) APRL PathLabs Private Limited, a step-down subsidiary company j) Chanre Laboratory Private Limited, a step-down subsidiary company k) Shahbazkers Diagnostic Centre Private Limited, a sub5idiary company (w.e.f. May 01, 2026) I) Dr. Lal Pathlabs FZCO, a subsidiary company (w.e.f. June 12, 2026) m) Sunshine Health care, Ghana (w.e.f. August 04, 2026) a step-down subsidiary company n) Dr Lal Pathlabs Indomed LLC (w.e.f. August 19, 2026) a step-down subsidiary company Regd. Office: One lnternatlonal Center, Tower 3, 31st floor, Senapati Bapat Marg. E!phinstone Road (West), Mumba1"'400 013, Maharashtra, India. Deloitte Haskins & Sells LLP is registered wlth Limited Liability having LLP identification No: MS..8737 Annexure-A
Page 13
Annexure 8' Or. Lal Patht.abs Limited Stand.-htne Ca$h flow Statement (INR. In minions exeeµt ,as stated) Year to date figlJre<J for Vear to date figures fer Particulars the i;:urrent petrlod ended thu previous perl«J 30 September, 2026 ended 30 septemberr 2025 (Unaudited) {Unaudited) Cash nows from operating activlties Profit for the period J,456 2,750 Adjustments for: T{IX expense 1,176 922 tnterest income (321} (309) Rental income from i'nvestn'leritproperty {17} (17) D!Vidend Income from a subsidiary company (16) . Net gain on sale or fair valuaUon cf Investments (at FVTPL) (194) (145) Net Gain on sale of investments {nel) (2) (Proflt)/Loss on disposal/ discard of property, plant and equipment (net} 2 (2) Expense recognised In respect of employee share based compensation 89 138 Finance costs 130 91 Depredation and ;:;rno,tlsatlon expense 832 713 Provision for lmpairr."_ent of trade receivables and advances 140 9 Bad debts and advances wrilten off 3 13 Operattng profit before working capital and other changes 5,278 4,163 Chan9u in working capital! Adjustment for (increa:se)/decrease In 1:,perating assets: (Increase)/DecreaS!i!' in inventories (113) (137) (Increase)/Decrease In trade receivables (331} (179) {I11crease)/Decrease in loans (3) (7) (Increase)/Decrease in other financial ass.e::s (10) (26) (1ncraase)/Decrease in other essuts {32) (38) AdjU9ttnent; for lncrease/(decrease) In opnratlng llabllltlos: Incroose/(decre,:,se) lh trode payables 28 106 :ncrease/(decrease) in other Financial Fabmtles (112) 26 !ncre.;i:se/{decrease) in provisions 96 56 lncreasel(ctecrease) 1n other liabll!tle1> (20 (109 Cash generated from ,operatioos 4,781 3,855 1ncome taxes paid (net) (911) !779) Net cash generated from operating actMtias (a) 3,870 3,076 cash flows from investing activities Payments for purchase of property, pl11nt and equipm,.nt (311) (1,327} ProceeCs from disposal cf property, plant and equ!pr, ·_ ,, 3 4 Payments for purchase of other !ntangtb!e assets (6) (45) Dlvidend received from a subsld!ary company 16 . Interest received 392 452 Rental Income from lnvestmet'\t property 17 17 Investment In subsldaries (700} . r;ryments for purchase of Investments In mutual funds (5,150) (2,664) Proceeds f;or:'! sale of investments in mutual funds 4,.::.3a 1,322 Bank deposlts p!aced with the banks {5,542) (7,307) Bank deposits With bar.ks encashe-d 5,073 5,776 Net cash used in Investing activities {b) (1,770} (3,7?2) Cash nows from financing activities: I Proceeds from exercise of share options 162 177 Repayment of lease llab!lity (185) (176) Interest paid on lease liability {127) (90) Interest paid . (1) D!V!dend paid on eqwty shares (1,503) (1,001) Net cash used in financing adivitles (c} (1,653) (1,091) Net increase/ (decrease) in cash and cash equivalents (a+b+c) 447 (1,767) cash and cash CQU!valents at the beginning Of the year 2,344 2,666 Cash and <:ash equivalents ;,,t the end of the period/year 2,791 .,. Components of cash and cash equivalents: Cash on hand 12 13 Balance with scheduled ban",,::s: • on current accounts 1,590 132 deposits with maturity of less than 3 month$ 1,189 734 Total cash and cash equivalents in Cash Flow Statement 21791 879 PS
Page 14
ANNEXURE - B DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED JULY 13, 2023: SN Particulars Ms. Vasuta Agarwal 1 Reasons for change viz appointment/ reappointment, resignation, removal, death or otherwise Appointment of Ms. Vasuta Agarwal as an Additional Director designated as a Non- Executive Independent Director on the Board of the Company 2 Date of Appointment/ Re-appointment & term of appointment/ re-appointment Date of Appointment: November 04, 2026 Term of Appointment: Appointment of Ms. Vasuta Agarwal as an Independent Director shall be effective from November 04, 2026 for a term of three (3) consecutive years, subject to the approval of Members of the Company 3 Brief Profile (in case of appointment) Ms. Vasuta Agarwal is a business and technology leader with experience across artificial intelligence, digital advertising, strategy and business operations. She is Chief Revenue Officer at Gnani.ai, where she leads growth and market expansion for a compan y building enterprise AI solutions for India and global markets. Before joining Gnani.ai, Ms. Vasuta has also worked with InMobi, McKinsey & Company and Intel. She holds a PGDM in Business Administration and Management from the Indian Institute of Management Bangalore and a bachelor's degree in engineering from Birla In stitute of Technology and Science, Pilani. Her recognition includes the Economic Times 40 Under Forty list, Campaign Asia's 40 Under 40, the Economic Times Women Ahead list and IMPACT's list of influential women in media, marketing and advertising. Ms. Vasuta Agarwal is on the board of IndiaMART InterMESH Limited, Kaya Limited, Iglulabs Software Private Limited and Valetez Services Private Limited 4 Disclosure of relationships between directors (in case of appointment of a director) None
Page 15
ANNEXURE - C DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED JULY 13, 2023: SN Particulars Details 1 Name of the target entity, details in brief such as size, turnover etc. Dr. Lal PathLabs FZCO, Dubai, United Arab Emirates (“LPL Dubai ”), is a W holly Owned Subsidiary of Dr. Lal PathLabs Limited (“LPL”). It was incorporated to make strategic investments in diagnostics and allied activities, including potential acquisitions, tie-ups or joint ventures. LPL Dubai has invested in Sunshine Healthcare Limited, Ghana (“SHL”), which became its subsidiary following the investment. Turnover of LPL Dubai: Not Applicable, since it was incorporated on June 12, 2026. Turnover of SHL (In INR): FY 26: 244 Mn. FY 25: 240 Mn. FY 24: 217 Mn. 2 Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” LPL Dubai is Wholly Owned Subsidiary of LPL, a related party of LPL. The proposed transactions are in the nature of related party transaction and will be on an arm’s length basis. 3 Industry to which the entity being acquired belongs Healthcare Diagnostics 4 Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) The proposed investment is intended for meeting business and operational requirements of LPL Dubai, including making further investment in its Subsidiary, SHL. 5 Brief details of any governmental or regulatory approvals required for the acquisition The Company will obtain required regulatory approvals, if required, from the authorities in the relevant jurisdictions. 6 Indicative time period for completion of the acquisition The transaction is expected to be completed by March 31, 2027, or such other dates as mutually agreed between the parties. 7 Consideration - whether cash consideration or share swap or any other form and details of the same Cash Consideration 8 Cost of acquisition and/or the price at which the shares are acquired Investment of an amount upto INR 49.5 Crores in LPL Dubai . (Including further investment of an amount upto INR 30 Crores in SHL by LPL Dubai)
Page 16
9 Percentage of shareholding / control acquired and / or number of shares acquired LPL Dubai shall continue to remain Wholly Owned Subsidiary of LPL. 10 Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) LPL Dubai was incorporated on June 12, 2026, under the Company Regulations of the DMCC Authority, Dubai, UAE, to strategically invest in Diagnostics and allied activities. This includes exploring potential acquisitions, tie -ups, or joint ventures. SHL was incorporated on September 07, 2010, under the laws of Ghana and is engaged in business of providing Healthcare/ Diagnostics services. Turnover: As mentioned in Clause 1 above